Sam Brusco, Associate Editor09.06.23
Moximed has announced the first commercial cases completed with its MISHA knee system, an implantable shock absorber (ISA) for patients with medial knee osteoarthritis (OA).
MISHA is indicated to treat knee OA patients who couldn’t get relief from non-surgical or surgical treatment, experience pain that interferes with daily activities, and are ineligible or unwilling for joint replacement due to age or absence of advanced OA. Moximed said until MISHA entered the market in April 2023, there were limited treatment options for knee OA when conservative ones failed.
“We’ve had unsolicited online requests for access to the MISHA Knee System from over one hundred surgeons across the U.S., and we receive several online patient inquiries every day,” Anton Clifford, Ph.D., founder and CEO of Moximed told the press. “Despite this broad enthusiasm, our roll out plan remains focused on delivering high quality education to our surgeon users, and I’m delighted to see our first surgeons represent both top-tier academic centers and high-caliber private practices.”
Dennis C. Crawford, MD, Ph.D., Professor of Orthopaedics and Rehabilitation, School of Medicine, Oregon Health and Science University, treated the first commercial patient.
“I am honored to have treated the first MISHA patient,” he said. “My first patient, in his 40s, presented with medial meniscal pathology, significant medial knee pain, and mild joint space loss. Prior to the MISHA Knee System being available, I had no good options for this patient. At the two-week post-operative visit, he had already recovered full range of motion, was fully weight bearing, and was walking comfortably,” said Dr. Crawford. “This outcome is consistent with the pivotal study results, and I now look forward to including the MISHA Knee System as a regular part of my treatment algorithm.”
Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation.
MISHA is indicated to treat knee OA patients who couldn’t get relief from non-surgical or surgical treatment, experience pain that interferes with daily activities, and are ineligible or unwilling for joint replacement due to age or absence of advanced OA. Moximed said until MISHA entered the market in April 2023, there were limited treatment options for knee OA when conservative ones failed.
“We’ve had unsolicited online requests for access to the MISHA Knee System from over one hundred surgeons across the U.S., and we receive several online patient inquiries every day,” Anton Clifford, Ph.D., founder and CEO of Moximed told the press. “Despite this broad enthusiasm, our roll out plan remains focused on delivering high quality education to our surgeon users, and I’m delighted to see our first surgeons represent both top-tier academic centers and high-caliber private practices.”
Dennis C. Crawford, MD, Ph.D., Professor of Orthopaedics and Rehabilitation, School of Medicine, Oregon Health and Science University, treated the first commercial patient.
“I am honored to have treated the first MISHA patient,” he said. “My first patient, in his 40s, presented with medial meniscal pathology, significant medial knee pain, and mild joint space loss. Prior to the MISHA Knee System being available, I had no good options for this patient. At the two-week post-operative visit, he had already recovered full range of motion, was fully weight bearing, and was walking comfortably,” said Dr. Crawford. “This outcome is consistent with the pivotal study results, and I now look forward to including the MISHA Knee System as a regular part of my treatment algorithm.”
Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation.